Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women

Beatrice A. Chen, Jingyang Zhang, Holly M. Gundacker, Craig Hendrix, Craig J. Hoesley, Robert A. Salata, Charlene S. Dezzutti, Ariane Van Der Straten, Wayne B. Hall, Cindy E. Jacobson, Sherri Johnson, Ian Mcgowan, Annalene M. Nel, Lydia Soto-Torres, Mark A Marzinke

Research output: Contribution to journalArticle

Abstract

Background Postmenopausal women have unique sociobiological human immunodeficiency virus (HIV) risks. We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women. Methods We enrolled 96 HIV-negative postmenopausal US women in a phase 2a double-blind, randomized (3:1) trial of monthly VRs containing 25 mg DPV or placebo used continuously for 12 weeks. We assessed safety by adverse events (AEs). DPV concentrations were quantified in plasma and vaginal fluid. Steady-state concentrations were analyzed at 4, 8, and 12 weeks using repeated measures ANOVA. We assessed acceptability by self-report. Results We found no differences in the proportion of women with related grade 2 or higher reproductive system AEs (DPV: 6/72 (8%), placebo: 3/24 (13%), P =.68) or grade 3 or higher AEs (DPV: 4/72 (6%), placebo: 0/24 (0%), P =.57). In the DPV arm, 2/72 (3%) declined to resume product use due to AEs. Median DPV concentrations in plasma (262.0 pg/mL at week 12) and vaginal fluid (40.6 ng/mg at week 12) were constant over 12 weeks and exceeded the in vitro 50% effective concentration by 5000-fold in vaginal fluid by week 4. VR acceptability was high; 84/93 (90%) "very much liked or liked" the VR. Conclusions DPV VRs were safe, well tolerated, and acceptable in postmenopausal women. Plasma concentrations were comparable to published data on DPV use in reproductive-age women (median plasma concentration: 264 pg/mL). Given the reassuring safety and pharmacokinetic data, the DPV VR is promising for preexposure prophylaxis in postmenopausal women. Clinical Trials Registration NCT02010593.

Original languageEnglish (US)
Pages (from-to)1144-1151
Number of pages8
JournalClinical Infectious Diseases
Volume68
Issue number7
DOIs
StatePublished - Mar 19 2019

Fingerprint

Female Contraceptive Devices
Pharmacokinetics
Safety
Placebos
TMC120-R147681
HIV
Anti-Infective Agents
Self Report
Analysis of Variance
Clinical Trials

Keywords

  • dapivirine
  • menopause
  • microbicide
  • pre-exposure prophylaxis
  • vaginal rings

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women. / Chen, Beatrice A.; Zhang, Jingyang; Gundacker, Holly M.; Hendrix, Craig; Hoesley, Craig J.; Salata, Robert A.; Dezzutti, Charlene S.; Van Der Straten, Ariane; Hall, Wayne B.; Jacobson, Cindy E.; Johnson, Sherri; Mcgowan, Ian; Nel, Annalene M.; Soto-Torres, Lydia; Marzinke, Mark A.

In: Clinical Infectious Diseases, Vol. 68, No. 7, 19.03.2019, p. 1144-1151.

Research output: Contribution to journalArticle

Chen, BA, Zhang, J, Gundacker, HM, Hendrix, C, Hoesley, CJ, Salata, RA, Dezzutti, CS, Van Der Straten, A, Hall, WB, Jacobson, CE, Johnson, S, Mcgowan, I, Nel, AM, Soto-Torres, L & Marzinke, MA 2019, 'Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women', Clinical Infectious Diseases, vol. 68, no. 7, pp. 1144-1151. https://doi.org/10.1093/cid/ciy654
Chen, Beatrice A. ; Zhang, Jingyang ; Gundacker, Holly M. ; Hendrix, Craig ; Hoesley, Craig J. ; Salata, Robert A. ; Dezzutti, Charlene S. ; Van Der Straten, Ariane ; Hall, Wayne B. ; Jacobson, Cindy E. ; Johnson, Sherri ; Mcgowan, Ian ; Nel, Annalene M. ; Soto-Torres, Lydia ; Marzinke, Mark A. / Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women. In: Clinical Infectious Diseases. 2019 ; Vol. 68, No. 7. pp. 1144-1151.
@article{734e45f5cd534bdab1fcb51b3792f88a,
title = "Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women",
abstract = "Background Postmenopausal women have unique sociobiological human immunodeficiency virus (HIV) risks. We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women. Methods We enrolled 96 HIV-negative postmenopausal US women in a phase 2a double-blind, randomized (3:1) trial of monthly VRs containing 25 mg DPV or placebo used continuously for 12 weeks. We assessed safety by adverse events (AEs). DPV concentrations were quantified in plasma and vaginal fluid. Steady-state concentrations were analyzed at 4, 8, and 12 weeks using repeated measures ANOVA. We assessed acceptability by self-report. Results We found no differences in the proportion of women with related grade 2 or higher reproductive system AEs (DPV: 6/72 (8{\%}), placebo: 3/24 (13{\%}), P =.68) or grade 3 or higher AEs (DPV: 4/72 (6{\%}), placebo: 0/24 (0{\%}), P =.57). In the DPV arm, 2/72 (3{\%}) declined to resume product use due to AEs. Median DPV concentrations in plasma (262.0 pg/mL at week 12) and vaginal fluid (40.6 ng/mg at week 12) were constant over 12 weeks and exceeded the in vitro 50{\%} effective concentration by 5000-fold in vaginal fluid by week 4. VR acceptability was high; 84/93 (90{\%}) {"}very much liked or liked{"} the VR. Conclusions DPV VRs were safe, well tolerated, and acceptable in postmenopausal women. Plasma concentrations were comparable to published data on DPV use in reproductive-age women (median plasma concentration: 264 pg/mL). Given the reassuring safety and pharmacokinetic data, the DPV VR is promising for preexposure prophylaxis in postmenopausal women. Clinical Trials Registration NCT02010593.",
keywords = "dapivirine, menopause, microbicide, pre-exposure prophylaxis, vaginal rings",
author = "Chen, {Beatrice A.} and Jingyang Zhang and Gundacker, {Holly M.} and Craig Hendrix and Hoesley, {Craig J.} and Salata, {Robert A.} and Dezzutti, {Charlene S.} and {Van Der Straten}, Ariane and Hall, {Wayne B.} and Jacobson, {Cindy E.} and Sherri Johnson and Ian Mcgowan and Nel, {Annalene M.} and Lydia Soto-Torres and Marzinke, {Mark A}",
year = "2019",
month = "3",
day = "19",
doi = "10.1093/cid/ciy654",
language = "English (US)",
volume = "68",
pages = "1144--1151",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women

AU - Chen, Beatrice A.

AU - Zhang, Jingyang

AU - Gundacker, Holly M.

AU - Hendrix, Craig

AU - Hoesley, Craig J.

AU - Salata, Robert A.

AU - Dezzutti, Charlene S.

AU - Van Der Straten, Ariane

AU - Hall, Wayne B.

AU - Jacobson, Cindy E.

AU - Johnson, Sherri

AU - Mcgowan, Ian

AU - Nel, Annalene M.

AU - Soto-Torres, Lydia

AU - Marzinke, Mark A

PY - 2019/3/19

Y1 - 2019/3/19

N2 - Background Postmenopausal women have unique sociobiological human immunodeficiency virus (HIV) risks. We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women. Methods We enrolled 96 HIV-negative postmenopausal US women in a phase 2a double-blind, randomized (3:1) trial of monthly VRs containing 25 mg DPV or placebo used continuously for 12 weeks. We assessed safety by adverse events (AEs). DPV concentrations were quantified in plasma and vaginal fluid. Steady-state concentrations were analyzed at 4, 8, and 12 weeks using repeated measures ANOVA. We assessed acceptability by self-report. Results We found no differences in the proportion of women with related grade 2 or higher reproductive system AEs (DPV: 6/72 (8%), placebo: 3/24 (13%), P =.68) or grade 3 or higher AEs (DPV: 4/72 (6%), placebo: 0/24 (0%), P =.57). In the DPV arm, 2/72 (3%) declined to resume product use due to AEs. Median DPV concentrations in plasma (262.0 pg/mL at week 12) and vaginal fluid (40.6 ng/mg at week 12) were constant over 12 weeks and exceeded the in vitro 50% effective concentration by 5000-fold in vaginal fluid by week 4. VR acceptability was high; 84/93 (90%) "very much liked or liked" the VR. Conclusions DPV VRs were safe, well tolerated, and acceptable in postmenopausal women. Plasma concentrations were comparable to published data on DPV use in reproductive-age women (median plasma concentration: 264 pg/mL). Given the reassuring safety and pharmacokinetic data, the DPV VR is promising for preexposure prophylaxis in postmenopausal women. Clinical Trials Registration NCT02010593.

AB - Background Postmenopausal women have unique sociobiological human immunodeficiency virus (HIV) risks. We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women. Methods We enrolled 96 HIV-negative postmenopausal US women in a phase 2a double-blind, randomized (3:1) trial of monthly VRs containing 25 mg DPV or placebo used continuously for 12 weeks. We assessed safety by adverse events (AEs). DPV concentrations were quantified in plasma and vaginal fluid. Steady-state concentrations were analyzed at 4, 8, and 12 weeks using repeated measures ANOVA. We assessed acceptability by self-report. Results We found no differences in the proportion of women with related grade 2 or higher reproductive system AEs (DPV: 6/72 (8%), placebo: 3/24 (13%), P =.68) or grade 3 or higher AEs (DPV: 4/72 (6%), placebo: 0/24 (0%), P =.57). In the DPV arm, 2/72 (3%) declined to resume product use due to AEs. Median DPV concentrations in plasma (262.0 pg/mL at week 12) and vaginal fluid (40.6 ng/mg at week 12) were constant over 12 weeks and exceeded the in vitro 50% effective concentration by 5000-fold in vaginal fluid by week 4. VR acceptability was high; 84/93 (90%) "very much liked or liked" the VR. Conclusions DPV VRs were safe, well tolerated, and acceptable in postmenopausal women. Plasma concentrations were comparable to published data on DPV use in reproductive-age women (median plasma concentration: 264 pg/mL). Given the reassuring safety and pharmacokinetic data, the DPV VR is promising for preexposure prophylaxis in postmenopausal women. Clinical Trials Registration NCT02010593.

KW - dapivirine

KW - menopause

KW - microbicide

KW - pre-exposure prophylaxis

KW - vaginal rings

UR - http://www.scopus.com/inward/record.url?scp=85063076790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063076790&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy654

DO - 10.1093/cid/ciy654

M3 - Article

C2 - 30289485

AN - SCOPUS:85063076790

VL - 68

SP - 1144

EP - 1151

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -